Molecular Imaging of Cerebrovascular Lesions

Inflammation is a key component in the pathogenesis of cerebrovascular lesions. Two agents have emerged as promising possibilities for imaging cerebrovascular lesions. These agents are ferumoxytol and myeloperoxidase (MPO)-specific paramagnetic magnetic resonance (MR) contrast agent. Ferumoxytol is...

Full description

Saved in:
Bibliographic Details
Published inTranslational stroke research Vol. 5; no. 2; pp. 260 - 268
Main Authors Chalouhi, Nohra, Jabbour, Pascal, Magnotta, Vincent, Hasan, David
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.04.2014
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1868-4483
1868-601X
1868-601X
DOI10.1007/s12975-013-0291-0

Cover

Loading…
More Information
Summary:Inflammation is a key component in the pathogenesis of cerebrovascular lesions. Two agents have emerged as promising possibilities for imaging cerebrovascular lesions. These agents are ferumoxytol and myeloperoxidase (MPO)-specific paramagnetic magnetic resonance (MR) contrast agent. Ferumoxytol is an iron oxide nanoparticle coated by a carbohydrate shell that is used in MRI studies as an inflammatory marker as it is cleared by macrophages. Ferumoxytol-enhanced MRI allows noninvasive assessment of the inflammatory status of cerebral aneurysms and arteriovenous malformations and, possibly, may differentiate “unstable” lesions that require early intervention from “stable” lesions that can be safely observed. Several pilot studies have also suggested that MPO-specific paramagnetic MR contrast agent, di-5-hydroxytryptamide of gadopentetate dimeglumine, may allow imaging of inflammation in the wall of saccular aneurysms in animal models. However, studies in human subjects have yet to be performed. In this paper, we review current data regarding ferumoxytol-enhanced MRI and MPO-specific paramagnetic MR contrast agent and discuss current and future applications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1868-4483
1868-601X
1868-601X
DOI:10.1007/s12975-013-0291-0